Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Eplontersen in Healthy Japanese Participants
NCT04302064Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2020
- Primary completion
- Sep 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Transthyretin amyloidosis (ATTR) comparing Eplontersen with Placebo (2 arms). Primary endpoints: Percentage of Participants with at Least One Treatment-emergent Adverse Event up to 92 days, Percentage of Participants with TEAEs Potentially Related to Study Drug up to 92 days and 1 more. Started Apr 2020; status: completed.
02
Drugs
eplontersen
03
Conditions
Transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT04302064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04302064.